Cognitive impairment and parkinsonism due to use of sodium valporate;Cognitieve stoornissen en parkinsonisme bij gebruik van valproïnezuur

Tijdschrift voor Gerontologie en Geriatrie

Volumn 40, Issue 1, 2009, Pages 29-33

  Schrer, L ^a,b,c   Middeljans Tijssen, C W ^a,c   Hengstman, G J D ^a,d   Rikkert, M G M Olde ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

Author keywords

Cognitive impairment; Parkinsonism; Valproate

Indexed keywords

EID: 61849093600     PISSN: 01679228     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03088474     Document Type: Article

References (25)

1. de la Court, Breteler MM, Meinardi H, Hauscr WA, Hofman A. Prevalence of epilepsy in the elderly: the Rotterdam Study. Epilepsia 1996 Feb;37(2):141-7.
2. Brodie MJ, Kwan P. Epilepsy in elderly people. BMJ 2005 Dec 3;331(7528):1317-22.
3. Hauser WA, Annegers JE Risk factors for epilepsy. Epilepsy Res Suppl 1991;4:45-52.
4. Loiseau J, Loiseau P, Duche B, Guyot M, Darti-gues JF, Aublet B. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990 Mar;27(3):232-7.
5. Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003;20(11):791-803.
6. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000 Apr 22;355(9213):1441-6.
7. Roberts MA, Godfrey JW, Caird FI. Epileptic seizures in the elderly: I. Aetiology and type of seizure. Age Ageing 1982 Feb;11(1):24-8.
8. Franson KL, Hay DP, Neppe V, Dahdal WY, Mirza WU, Grossberg GT, et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 1995 Jul;7(1):38-48.
9. Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia 2000;41 Suppl 9:31-5.
10. Perucca E, Aldenkamp A, Tallis R, Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 2006;184:28-37.
11. Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990 Nov 24;336(8726):1271-4.
12. Meinardi MC, van den Berg GB, Groenhuijzen A, Maas HAAM, Wolfhagen FHJ. Ned Tijdschr Geneeskd. 2008;152:278-82.
13. Hommet C, Mondon K, de TB, Constans T. Reversible cognitive and neurological symptoms during valproic acid therapy. J Am Geriatr Soc 2007 Apr;55(4):628.
14. Masmoudi K, Gras-Champel V, Bonnet I, Pannier M, Masson H, Rosa A, et al. [Dementia and extrapyramidal problems caused by long-term valproic acid]. Therapie 2000 Sep;55(5):629-34.
15. Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006 Jan;39(1):9-12.
16. Ristic AJ, Vojvodic N, Jankovic S, Sindelic A, Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006 Dec;47(12):2183-5.
17. Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004 Apr 27;62(8):1435-7.
18. Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007 Feb;78(2):147-51.
19. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996 Sep;47(3):626-35.
20. Ikebe S, Tanaka M, Ohno K, Sato W, Hattori K, Kondo T, et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 1990 Aug 16;170(3):1044-8.
21. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989 Sep 29;163(3):1450-5.
22. Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989 Dec;26(6):719-23.
23. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990 Mar;54(3):823-7.
24. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990 Dec;55(6):2142-5.
25. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985 Jul 1;36(26):2503-8.